Nabla Bio secures $26m in Series A funding round
Pharmaceutical Technology
MAY 15, 2024
Nabla Bio has secured $26m in a Series A financing round led by Radical Ventures, for generative protein designing.
Wed.May 15, 2024
245 
Eisai sets new revenue target for Alzheimer’s drug Leqembi
Bio Pharma Dive
MAY 15, 2024
The annual forecast, which comes as Eisai and Biogen have begun submitting a more convenient form of Leqembi for approval, looks “more realistic” than previous guidance, according to Jefferies analysts.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA clears IND for Verismo Therapeutics’ CAR-T therapy
Pharmaceutical Technology
MAY 15, 2024
Verismo Therapeutics announced FDA clearance for a Phase I trial of its CAR-T therapy to treat non-Hodgkin lymphoma.
Scientists Reveal Just How Far Plastic Can Reach Into Your Lungs
AuroBlog - Aurous Healthcare Clinical Trials blog
MAY 15, 2024
Miniscule fragments of plastic pollution invade the human body every day without our knowing it, not just from eating and drinking but from simply breathing. By some estimates, the average person inhales a credit card’s worth of plastic every week with unknown health effects.
Bridging Innovation & Patient Care: The Growing Role of AI
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
FDA rejects label expansion for Dynavax’s hepatitis B vaccine
Pharmaceutical Technology
MAY 15, 2024
The US agency rejected the expanded use of Dynavax’s vaccine for adults on haemodialysis, citing insufficient efficacy and safety data.
PCI issues guidelines for institutions prior to commencement of inspection process
AuroBlog - Aurous Healthcare Clinical Trials blog
MAY 15, 2024
The Pharmacy Council of India (PCI) has issued guidelines for the institutions related to the inspection process for the academic year 2024-25, mandating that the students and the faculties should have their smart cards and the infrastructure of the institutions should have mandatory active Quick Response (QR) code at the time of inspection.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
PCI issues guidelines for institutions prior to commencement of inspection process
AuroBlog - Aurous Healthcare Clinical Trials blog
MAY 15, 2024
The Pharmacy Council of India (PCI) has issued guidelines for the institutions related to the inspection process for the academic year 2024-25, mandating that the students and the faculties should have their smart cards and the infrastructure of the institutions should have mandatory active Quick Response (QR) code at the time of inspection.
Bolt Biotherapeutics to lay off staff, abandon lead ADC candidate
Bio Pharma Dive
MAY 15, 2024
The company will cut its workforce by half and shuffle leadership as it discontinues testing of the drug trastuzumab imbotolimod.
GLP-1 receptor agonist sales expected to reach $125bn by 2033
Pharmaceutical Technology
MAY 15, 2024
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of incretin mimetic medicines for the treatment of Type 2 diabetes and obesity.
Novo Holdings buys stake in life sciences tools company; BioMarin lays off 170
Bio Pharma Dive
MAY 15, 2024
The parent of Novo Nordisk is acquiring 60% ownership of Single Use Support. Elsewhere, ICER is raising questions about a PTSD drug and BioMarin is cut jobs after a pipeline review.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
US study reveals interferon combinations cause lupus symptoms and affect treatment
Pharma Times
MAY 15, 2024
The autoimmune disease, which affects 1.
Circular RNA: Vaccines, therapeutics and biomarkers could be revolutionised
Pharmaceutical Technology
MAY 15, 2024
CircRNA is still in early days of development, but could be in trials as vaccines, therapeutics and biomarkers in the next few years.
NIHR and TJBCM announce new funding initiative for novel brain tumour research
Pharma Times
MAY 15, 2024
The condition is the ninth most common cancer in the UK and affects 12,300 people annually
May 15, 2024: This Week’s PCT Grand Rounds to Feature the CardioHealth Alliance
Rethinking Clinical Trials
MAY 15, 2024
Dr. Ken Mahaffey, Dr. Nishant Shah, and Dr. Neha Pagidipati In this Friday’s PCT Grand Rounds, Ken Mahaffey of Stanford University and Nishant Shah and Neha Pagidipati of Duke University will present “CardioHealth Alliance: A Platform to Improve Care.” The Grand Rounds session will be held on Friday, May 17, 2024, at 1:00 pm eastern.
Eisai begins rolling submission to FDA for injectable version of Leqembi
Pharmaceutical Technology
MAY 15, 2024
Eisai has initiated a rolling submission to FDA for approval of a more convenient version of its Alzheimer’s disease treatment Leqembi.
GSK, UK govt put £130m into antimicrobial resistance fight
pharmaphorum
MAY 15, 2024
GSK has become the first founding partner of the new Fleming Initiative, which aims to tackle the rising threat of antimicrobial resistance (AMR) and is also backed by the UK government.
Companies prepare for ADC trial readouts at ASCO 2024
Pharmaceutical Technology
MAY 15, 2024
Several companies have announced data presentations at the 2024 ASCO annual meeting for their late-stage and approved programs.
Home testing devices for sleep apnoea backed for NHS use
pharmaphorum
MAY 15, 2024
Five home-testing devices to diagnose sleep apnoea, which can affect the health of around 2.5 million adults in the UK, have been recommended for NHS use by NICE.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
OCT Europe: Unless everyone is benefiting, what is the point?
Pharmaceutical Technology
MAY 15, 2024
A big topic at Arena International’s Outsourcing in Clinical Trials Europe 2024 is how everyone should benefit from clinical research.
Case Study: MHRA
pharmaphorum
MAY 15, 2024
MHRA's innovative regulatory approach enables Nuwiq's accelerated clinical trial timeline for haemophilia patients. Learn how their flexible approach is speeding access to new treatments.
Enveric Biosciences to out-license psilocin prodrug to MindBio
Pharmaceutical Technology
MAY 15, 2024
Enveric Biosciences has entered a non-binding term sheet with MindBio Therapeutics to out-license a class of psilocin prodrugs.
FDA clears BMS’ Breyanzi for follicular lymphoma
pharmaphorum
MAY 15, 2024
BMS gets another FDA approval for its CD19-directed CAR-T Breyanzi, this time as a third-line or later therapy for follicular lymphoma
University of Nottingham develops 3D-printed medication method
Pharmaceutical Technology
MAY 15, 2024
The University of Nottingham in the UK has announced the development of a new method enabling the creation of 3D-printed personalised pills.
FDA clears Roche self-collection system for HPV screening
pharmaphorum
MAY 15, 2024
The FDA has approved Roche's HPV self-sampling solution that the company says can tackle unequal access to screening that can put women at risk of cervical cancer
Moffitt and Fulgent Pharma partner on personalised cancer therapies
Pharmaceutical Technology
MAY 15, 2024
Moffitt Cancer Center and Fulgent Pharma have announced a partnership to enhance the development of personalised therapies for cancer.
Updated BIOSECURE Act draft clears House committee
pharmaphorum
MAY 15, 2024
House Oversight Committee passes BIOSECURE Act, which would restrict US companies from contracting with Chinese biotechs including WuXi AppTec, MGI and BGI
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
LogiPharma Europe 2024: World Courier President Talks Mitigating Supply Chain Risks
Pharmaceutical Commerce
MAY 15, 2024
In an interview with Pharma Commerce Editor Nicholas Saraceno at LogiPharma Europe, Nick Porter, President, World Courier discusses mitigating supply chain risks, the future of artificial intelligence in pharma logistics, and more.
AbbVie takes option on Gilgamesh psychedelics in $2bn deal
pharmaphorum
MAY 15, 2024
AbbVie joins a select group of big pharma groups working on psychedelic medicines, paying $65m on an option deal with Gilgamesh Pharma
New patent for Mallinckrodt Hosp drug INOMAX
Drug Patent Watch
MAY 15, 2024
Annual Drug Patent Expirations for INOMAX Inomax is a drug marketed by Mallinckrodt Hosp and is included in one NDA. It is available from one supplier.
Eisai, Biogen start delayed subcutaneous Leqembi filing
pharmaphorum
MAY 15, 2024
Eisai and Biogen have filed a rolling biologics license application in the US for a subcutaneous formulation of Alzheimer’s disease therapy Leqembi that was delayed by the FDA on procedural grounds.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Let's personalize your content